Angiocrine Bioscience provides a GMP‑compliant cell‑therapy platform that engineers endothelial and stromal cells to secrete angiocrine growth factors for tissue regeneration. The E‑CEL Therapies platform delivers autologous and allogeneic cell products targeting vascular remodeling and extracellular matrix repair across cardiac, hepatic, and musculoskeletal indications. It serves pharmaceutical, biotech, and academic partners developing regenerative treatment candidates.
Funding
$2.1M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founders
Product
Problem
Many chronic and degenerative diseases lack therapies that can actively regenerate damaged tissue, leaving patients reliant on symptomatic treatments that do not restore function. Conventional drug approaches often fail to address the underlying cellular loss or microvascular dysfunction that drives disease progression.
Solution
Angiocrine Bioscience leverages its proprietary E‑CEL Therapies platform to develop cell‑based products that harness the reparative signaling of endothelial and stromal cells. By engineering therapeutic cells to express angiocrine factors, the platform promotes vascular remodeling, extracellular matrix restoration, and functional tissue regeneration. The approach is designed to be adaptable across multiple organ systems, enabling targeted treatment of unmet medical needs such as ischemic injury, fibrotic disease, and age‑related degeneration. Preclinical validation demonstrates enhanced tissue repair and functional recovery, supporting a pathway toward clinical translation.
Target Audience
The primary customers are pharmaceutical and biotech companies seeking regenerative therapy candidates, as well as academic medical centers developing clinical protocols for tissue repair.
Features
- GMP‑compliant manufacturing pipeline for autologous and allogeneic therapeutic cell lines
- Engineered expression of angiocrine growth factors (e.g., VEGF, FGF, HGF) to stimulate endogenous repair mechanisms
- Scalable bioprocess that supports multiple tissue‑specific formulations (cardiac, hepatic, musculoskeletal)
- Integrated quality‑by‑design analytics for potency, viability, and cytokine release profiling
- Proprietary cell‑delivery vectors enabling targeted homing to injured microvasculature
- Robust preclinical models demonstrating accelerated angiogenesis, reduced fibrosis, and functional outcome improvement
- Modular platform architecture allowing rapid adaptation to new disease indications